News

Povetacicept reduces disease activity in MG mouse model

Povetacicept, a treatment for autoimmune diseases in the pipeline of Vertex Pharmaceuticals, reduced disease activity in a study with a mouse model of myasthenia gravis (MG) by lowering the levels of disease-causing antibodies in the bloodstream. Researchers also observed that povetacicept outperformed efgartigimod — approved as Vyvgart…

Vyvgart found effective for 3 triple-seronegative gMG patients

Treatment with Vyvgart (efgartigimod) eased hard-to-treat symptoms for a trio of women with generalized myasthenia gravis (gMG) who tested negative for three antibodies commonly seen in the disease, according to a case series from China. Per the researchers, “this report describes three patients with triple-[seronegative] gMG successfully treated with efgartigimod,”…

New telitacicept deal aims to advance MG therapy outside China

Vor Bio has signed an exclusive license agreement to develop and market Remegen’s telitacicept — a B-cell-targeting candidate for the treatment of myasthenia gravis (MG) and other autoimmune diseases driven by self-reactive antibodies — outside of China, Hong Kong, Macau, and Taiwan. Telitacicept has been approved…

Telitacicept named orphan drug in EU as MG therapy

Telitacicept, a B-cell-targeting therapy for myasthenia gravis (MG), has been granted orphan drug status in the European Union, according to its developer Remegen. Orphan drug designation, or ODD, is awarded to medications that treat conditions affecting fewer than 5 in 10,000 people in the EU. The designation’s…

Inspiratory muscle training, aerobic exercise aid lung function in MG

A six-week program that combines inspiratory muscle training (IMT) and aerobic exercise may improve respiratory function in adults with myasthenia gravis (MG), a study in Taiwan shows. Those who followed the training showed strengthened respiratory muscles, improved lung function, reduced breathlessness, and enhanced physical fitness over those who received…

FDA clears Phase 2 trial testing C5 inhibitor IM-101 in MG patients

The U.S. Food and Drug Administration (FDA) has cleared the launch of a Phase 2 clinical trial testing IM-101, ImmunAbs’ investigational therapy for myasthenia gravis (MG). The multicenter, placebo-controlled trial is expected to enroll up to 90 people with MG who will receive IM-101 or a placebo once monthly.

MG Awareness Month focuses on community, action

Organizations are holding events and activities in June in recognition of Myasthenia Gravis Awareness Month, an annual observance that aims to raise awareness of myasthenia gravis (MG), an autoimmune disease that affects 90,000-100,000 people in the U.S. alone. “Throughout June, Myasthenia Gravis News is recognizing awareness month with a…